The data we presented support a role for anti-CD38 therapy for the treatment of systemic autoimmune diseases, such as SLE, SSc, SS and AAV, not only in established disease, but also at the preclinical stage. The gene discussed is CD38; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.